StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) stock

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.70+0.00 (0.00%)

Close on Nov 17, 2026Market cap $103.06MP/E –Yield –

Unicycive Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Unicycive Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.61M, down 21.6% year over year. For fiscal 2025 it was $9.12M, down 54.4% from the year before. The highest annual figure on record is $20.01M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.12M-54.4%
FY2024Dec 31, 2024$20.01M+55.1%
FY2023Dec 31, 2023$12.90M+3.7%
FY2022Dec 31, 2022$12.44M+104.5%
FY2021Dec 31, 2021$6.08M+499.0%
FY2020Dec 31, 2020$1.02M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.79M+59.3%
Q1 FY2026Mar 31, 2026$1.61M-26.0%
Q4 FY2025Dec 31, 2025$2.25M-57.5%
Q3 FY2025Sep 30, 2025$2.96M-2.7%
Q2 FY2025Jun 30, 2025$1.75M-64.1%
Q1 FY2025Mar 31, 2025$2.17M-68.1%
Q4 FY2024Dec 31, 2024$5.29M+24.9%
Q3 FY2024Sep 30, 2024$3.05M-9.7%
Q2 FY2024Jun 30, 2024$4.87M+114.7%
Q1 FY2024Mar 31, 2024$6.81M+124.9%
Q4 FY2023Dec 31, 2023$4.23M+10.2%
Q3 FY2023Sep 30, 2023$3.37M-29.8%
Q2 FY2023Jun 30, 2023$2.27M+21.9%
Q1 FY2023Mar 31, 2023$3.03M+56.8%
Q4 FY2022Dec 31, 2022$3.84M+182.1%
Q3 FY2022Sep 30, 2022$4.80M+27.2%
Q2 FY2022Jun 30, 2022$1.86M+277.3%
Q1 FY2022Mar 31, 2022$1.93M+329.6%
Q4 FY2021Dec 31, 2021$1.36M+256.3%
Q3 FY2021Sep 30, 2021$3.78M+1142.1%
Q2 FY2021Jun 30, 2021$493.00K+170.9%
Q1 FY2021Mar 31, 2021$450.00K–
Q4 FY2020Dec 31, 2020$382.00K–
Q3 FY2020Sep 30, 2020$304.00K–
Q2 FY2020Jun 30, 2020$182.00K–

More Unicycive Therapeutics figures

See a number that looks wrong?